The EU Promotes Top Research In Biomedical Informatics To Support Individualised Medicine

INFOBIOMEDThe Commission of the European Union has funded with 4.85 million euros the Network of Excellence INFOBIOMED 'Structuring European Biomedical Informatics to Support Individualised Healthcare'. This pan-European project aims to develop tools and methods in Biomedical Informatics (BMI) and to create a stable and lasting structure for this discipline in Europe.

The idea of this project stems from the European BIOINFOMED study (5th Framework EU Programme), which was coordinated by the Institute of Health Carlos III, Madrid, Spain. This project carried out a prospective analysis of the relationships and synergy between Bioinformatics and Medical Informatics. The results of BIOINFOMED are reflected in the White Paper of the project, including a detailed R&D agenda for the advancement of BMI.

BMI is a discipline that is placed in the confluence of two disciplines that up to date have developed in an independent form, Bioinformatics and Medical Informatics. Although traditionally, Medical Informatics has been focused on the intersection between computer science and clinical medicine, and Bioinformatics has been predominantly centered on the intersection between computer science and biological research, the synergy between these two areas offers excellent opportunities for the advancement of personalised healthcare. The integration and exploitation of all the data and information generated at all levels by these disciplines requires a new synergetic approach that enables a two-way dialogue between them that comprises data, methods, technologies, tools and applications. BMI will help facilitate the translation of biological research results into clinical solutions.

Therefore the main purpose of INFOBIOMED Network is to enable the reinforcement of European BMI as an integrative discipline. BMI aims to create a common conceptual information space to further the discovery of novel diagnostic and therapeutic methods in the rapidly evolving arena of genomic medicine. The mission of BMI is to provide the technical and scientific infrastructure and knowledge to allow evidence-based, individualised healthcare using all relevant sources of information. Its implementation will help improve not only the treatment of diseases but also their diagnosis and prevention, also placing emphasis in public health and the reclassification of diseases. These foreseen benefits will improve health and quality of life of citizens and will probably have an effect on the efficiency of expenditure of the healthcare system.

The Network
INFOBIOMED is a 3-year project that started on January 2004. It includes 16 European organizations from 10 different countries, Belgium, Denmark, Germany, Great Britain, Greece, Italy, The Netherlands, Portugal, Spain, and Sweden.

The Network brings together research groups with different background, each leader in its field of expertise creating a multidisciplinary team providing a good working environment and enabling the collaborative approach that supports the consolidation of BMI as a crucial scientific discipline for future healthcare. The network is composed by: Fundació IMIM, Institut Municipal d’Investigació Mèdica, Instituto de Salud Carlos III, Karolinska Institute, Edinburgh University, Custodix, Universidad Politécnica de Madrid, Universidad de Aveiro, Foundation for Research and Technology-Hellas, Danish Centre for Health Telematics, Informa S.r.l, Heinrich-Heine-Universität Düsseldorf, Erasmus MC-University Medical Center Rotterdam, Hvidovre Hospital, Academisch Centrum Tandheelkunde Amsterdam, and AstraZeneca Research and Development. This project is coordinated by the Research Unit on Biomedical Informatics (GRIB) of the Institut Municipal d'Investigació Mèdica (IMIM) in Barcelona, Spain.

The Joint Programme of Activities in INFOBIOMED has been designed to first, cover all the significant aspects that are relevant to Medical Informatics and Bioinformatics and that have the potential to provide a space for synergy between them. These aspects are included in two separate blocks of activities, one for data interoperability and management and the other for methods, technologies and tools. Each block is divided in several activities that reflect the main different areas that require specific effort towards synergy: data interoperability and management and methods technologies and tools. This will require the integration and/or development of technologies that make possible this new approach to genomic medicine and preventive medicine. The first steps are to make a complete study of the state of the art and identification of the bottlenecks to then propose solutions for BMI.

The INFOBIOMED project applies a vertical as well as a horizontal approach to Biomedical Informatics, with the purpose of integrating data from all different areas, clinic, genetics, and environment thus giving a global perspective. This way all the knowledge gathered in the framework of these activities will be then tested into some 'vertical' pilot applications that aim to cover the whole range of information levels from molecule to population, from a practical perspective that works as test-bed for the integrative approach pursued. These pilots will allow to analyse the impact of BMI in key specific fields with the aim of investigating and knowing the requirements that these fields impose to BMI. Therefore, the application pilots intend to create a bi-directional dialogue between BMI and other health-related disciplines where BMI is used, in order to prevent the isolation of scientists of different disciplines and to foster the creation of a solid, durable scientific community. The four areas covered are pharmainformatics, genomics and microbiology, genomics and chronic inflammation, and genomics and colon cancer.

For further information, please visit:
www.infobiomed.net

Most Popular Now

Researchers Capture First Images of Oxyg…

Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful. Hypoxia, or starvation of oxygen, in solid tumors is also thought to be...

VTT Makes New Investments in Digital Hea…

VTT is launching new research activities in the area of digital health as part of the growing wellbeing and health technology ecosystem in Kuopio. The new initiative aims to create...

A New Method of Artificial Intelligence …

Despite the immense progress in the field of AI in recent years, we are still very far from human intelligence. Indeed, if current AI techniques allow to train computer agents...

FDA Informs Health Care Providers, Facil…

Today, the U.S. Food and Drug Administration is issuing a safety communication informing health care providers, facilities and patients about cybersecurity vulnerabilities identified for certain GE Healthcare Clinical Information Central...

eHealthWeek 2020 Croatia - Trusted Infor…

15 - 17 April 2020, Rovinj, Croatia. In its capacity of hosting the upcoming Presidency of the Council of the European Union, the Croatian Ministry of Health is in preparations to...

NHS IT Chiefs Set the Stage for a Year o…

3 - 4 March 2019, London, United Kingdom. NHS technology leaders are to kick off the second-ever Digital Health Rewired Conference and Exhibition on 3 - 4 March at the Olympia...

Siemens Healthineers Presents Solutions …

CT scanners with intelligent user guidance, AI-based software assistants for MRI and a lab system that revolutionizes workflows: Siemens Healthineers is showcasing its products and solutions according to the motto...

PatchAi Startup has Arrived in the Marke…

PatchAi - a startup that offers, thanks to Artificial Intelligence and Machine Learning, an empathic virtual assistant to patients participating in clinical trials - announced that it has closed two...

Digital Health App Medicus AI Earns CE C…

Medicus AI, the Vienna-based health tech company, has received a ​Class I Medical Device CE Mark for its mobile application. The CE certification mark confirms that Medicus AI conforms to...

FDA Authorizes Marketing of First Cardia…

Today, the U.S. Food and Drug Administration authorized marketing of software to assist medical professionals in the acquisition of cardiac ultrasound, or echocardiography, images. The software, called Caption Guidance, is...

Human Body-on-Chip Platform Enables In V…

Drug development is an extremely arduous and costly process, and failure rates in clinical trials that test new drugs for their safety and efficacy in humans remain very high. According...

AI in Drug Discovery Conference 2020

16 - 17 March 2020, London, UK. SMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London. AI-empowered machine learning technologies hold the potential...